Articles From: EPIRUS’ Remicade® Biosimilar Receives Final Approvals in India to EPR Properties Announces Pricing of Equity Offering


EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that it has received final marketing and manufacturing approvals for its Remicade ® (infliximab) biosimilar, BOW015, from the Drug Controller General of India (DCGI). BOW015 is the first infliximab biosimilar approved in India.
Sign-up for EPIRUS’ Remicade® Biosimilar Receives Final Approvals in India investment picks
Veeco Instruments Inc. (Nasdaq:VECO) announced today that Epistar Corporation (TSE:2448) has successfully evaluated and accepted the new TurboDisc® EPIK700™ Gallium Nitride (GaN) Metal Organic Chemical Vapor Deposition (MOCVD) system for the production of light emitting diodes (LEDs). “As the leader in LED technology and commercialization, it is vital that we continue to push our roadmap to reduce solid state lighting costs with the most innovative and efficient production solutions available,” said Dr.
Sign-up for Epistar Qualifies Veeco’s New EPIK700 MOCVD System for High Volume LED Production investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0958668001&sourceType=1 http://www.ccnmatthews.com/logos/20080922-epistem200.jpg MANCHESTER, UNITED KINGDOM --
Sign-up for Epistem Plc: Announcement of Collaborative Funding Agreement With Global Health Investment Fund I, LLC investment picks
2014/8/5
Epitome Pictures Starts Production on Open Heart For YTV in Canada and Teennick in the U.S. Canada NewsWire Brand new live-action Family Mystery Series from the Producers of Degrassi, and developed in association with marblemedia Ramona Barckert (2014 Canadian Screen Award winner) is Showrunner and Writer HALIFAX , LOS ANGELES , LONDON , TORONTO , VANCOUVER , Aug.
Sign-up for Epitome Pictures Starts Production on Open Heart For YTV in Canada and Teennick in the U.S. investment picks
2014/7/21
EPIX, the premium entertainment network, announced today that boxing great and entrepreneur Oscar De La Hoya will be the next guest on Personal with Bill Rhoden, the network’s special interview series hosted by the award-winning sports journalist with The New York Times .
Sign-up for EPIX Captures Oscar De La Hoya as He Defines Himself, Life In and Out of the Ring investment picks
2014/7/28
Premium entertainment network EPIX announced today that Forgotten Four: The Integration of Pro Football , an EPIX Original Documentary, will make its World Premiere on Tuesday, September 23, 2014, at 8PM ET .
Sign-up for EPIX Original Documentary Profiles Four African American Athletes Who Broke the Color Barrier investment picks
2014/9/16
Premium entertainment network EPIX announced today that Golden Globe and Emmy Award winner Jane Lynch (“Glee”) will lend her voice to the EPIX Original Documentary, To Russia With Love , that will make its World Premiere Wednesday, October 29 at 8PM ET .
Sign-up for EPIX Original Documentary To Russia with Love Explores LGBT Human Rights Journey as Seen Through Athletes’ Experience -- Premieres October 29 at 8PM ET investment picks
2014/9/23
Premium TV network EPIX and the National Hockey League (NHL®) announced today that they have formed a partnership to produce and distribute a two-part original series, debuting on EPIX in December 2014, that will bring hockey fans onto the ice and behind-the-scenes with the Chicago Blackhawks and Washington Capitals as they prepare to compete in the 2015 Bridgestone NHL Winter Classic®, and the Los Angeles Kings and San Jose Sharks on their road to the 2015 Coors Light NHL Stadium Series™. Produced by 52-time Emmy award winner Ross Greenburg , the series will offer viewers an exclusive look inside the world of the NHL, with strategically placed cameras and microphones providing an all-access pass to players’ homes, locker rooms, training rooms, and the arena.
Sign-up for EPIX Teams with National Hockey League for Two-Part Series, Debuting in December 2014 investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced, in conjunction with its development partner Eisai, that clinical data from the ongoing Phase 1 study of EPZ-6438 (E7438), an oral, small molecule inhibitor of EZH2, will be featured in a late-breaking oral presentation at the 26 th EORTC-AACR-NCI Symposium on Molecular Targets and Cancer Therapeutics, to be held November 18-21 in Barcelona, Spain.
Sign-up for Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Jason Rhodes, President and Chief Financial Officer, has resigned from the company, effective September 30, 2014.
Sign-up for Epizyme Announces Resignation of President and Chief Financial Officer Jason Rhodes investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced second quarter 2014 operating and financial results and reiterated 2014 guidance.
Sign-up for Epizyme Announces Second Quarter 2014 Financial Results and Provides Corporate Update investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the appointments of Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D. as Vice President, Business Development.
Sign-up for Epizyme Appoints Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D., as Vice President, Business Development investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas.
Sign-up for Epizyme Presents Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in five upcoming conferences in September: About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers.
Sign-up for Epizyme to Present at Upcoming Conferences in September investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming events in October: About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers.
Sign-up for Epizyme, Inc. to Present at Upcoming Events in October investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Wednesday, August 13, 2014 at 8:00 a.m. ET to report second quarter 2014 financial results and provide a corporate update.
Sign-up for Epizyme, Inc. to Report Second Quarter Financial Results and Provide Corporate Update on August 13, 2014 investment picks
2014/10/7
HERNDON, Va., Oct.
Sign-up for ePlus Achieves HP Gold Cloud Builder Specialist Designation investment picks
2014/9/10
HERNDON, Va., Sept.
Sign-up for ePlus Announces Changes to Board of Directors investment picks
2014/7/31
HERNDON, Va., July 31, 2014 (GLOBE NEWSWIRE) -- ePlus inc.
Sign-up for ePlus Announces First Quarter Fiscal Year 2015 Earnings Release Date and Conference Call investment picks
2014/9/23
HERNDON, Va., Sept.
Sign-up for ePlus Becomes an Authorized Surface Reseller in the Microsoft Devices Program investment picks
2014/9/25
HERNDON, Va., Sept.
Sign-up for ePlus Expands Managed Services Offering to Support Cisco Meraki Solutions investment picks
2014/8/18
HERNDON, Va., Aug.
Sign-up for ePlus Expands Presence in California With Acquisition of Evolve Technology Group investment picks
2014/9/18
HERNDON, Va., Sept.
Sign-up for ePlus Recognized by Cisco for Excellence in Customer Satisfaction in the United States investment picks
2014/8/6
Revenue increased 5% to $272.3 million, led by 6% growth in technology segment Gross margin expanded to 20.7% from 20.3%, driven by gross margin increase on products and services of 18.5% from 17.7% Earnings per diluted share of $1.25 includes gain on retirement of liability; excluding gain, non-GAAP earnings per diluted share was $1.14, up 17.5% from $0.97 per share HERNDON, Va., Aug.
Sign-up for ePlus Reports First Quarter Financial Results investment picks
2014/8/26
HERNDON, Va., Aug.
Sign-up for ePlus Selected by Surry County Public Schools for a Complete Collaboration Solution investment picks
2014/10/2
HERNDON, Va., Oct.
Sign-up for ePlus Technology Achieves Five Cisco Recertifications investment picks
2014/8/5
HERNDON, Va., Aug.
Sign-up for ePlus Technology Amends Credit Facility With GE Capital Commercial Distribution Finance investment picks
2014/8/4
HERNDON, Va., Aug.
Sign-up for ePlus to Present at the Canaccord Genuity 34th Annual Growth Conference investment picks
EPR Properties (NYSE:EPR) announced today that it has commenced an underwritten public offering of 3,200,000 of its common shares of beneficial interest.
Sign-up for EPR Properties Announces Equity Offering investment picks
EPR Properties (NYSE:EPR) announced today the pricing of its underwritten public offering of 3,200,000 of its common shares of beneficial interest at a price of $52.25 per share.
Sign-up for EPR Properties Announces Pricing of Equity Offering investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: EPIRUS’ Remicade® Biosimilar Receives Final Approvals in India to EPR Properties Announces Pricing of Equity Offering
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices